{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:46:48Z","timestamp":1793641608571,"version":"4.5.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.002","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T14:05:35Z","timestamp":1269957935000},"page":"187-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":218,"title":["Rituximab-Associated Infections"],"prefix":"10.1053","volume":"47","author":[{"given":"Juan C.","family":"Gea-Banacloche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.002_bib1","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib2","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/kel358","article-title":"Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years","volume":"45","author":"Strand","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib5","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib6","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib7","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib8","article-title":"A perspective on B-cell-targeting therapy for SLE","author":"Looney","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib10","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/TP.0b013e3181a235fd","article-title":"A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation","volume":"87","author":"Tyden","year":"2009","journal-title":"Transplantation"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006552.pub2","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","author":"Vidal","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajh.21343","article-title":"Incidence of hepatitis B reactivation following rituximab therapy","volume":"84","author":"Hanbali","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.12557","article-title":"Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy","volume":"93","author":"Targhetta","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001813-200501000-00012","article-title":"Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab","volume":"16","author":"Zell","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s002770100346","article-title":"Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report","volume":"80","author":"Ng","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","author":"Law","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib19","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib20","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","article-title":"Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab","volume":"99","author":"Goldberg","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2002-04-1271","article-title":"Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody","volume":"100","author":"Matteucci","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-008-0168-2","article-title":"Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature","volume":"88","author":"Yokoyama","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib24","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"Katsuya","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib25","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen","volume":"92","author":"Kolstad","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2007.00994.x","article-title":"Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma","volume":"80","author":"Venhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-3062.2008.00345.x","article-title":"Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient","volume":"11","author":"Kumar","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1440-1797.2009.01168.x","article-title":"Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection","volume":"14","author":"Shelton","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib31","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/rheumatology\/ken234","article-title":"Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis","volume":"47","author":"Teichmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/10428190902782210","article-title":"Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy","volume":"50","author":"Ganjoo","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2141.2009.07748.x","article-title":"Enterovirus infection of neuronal cells post-rituximab","volume":"146","author":"Kiani-Alikhan","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2257.2006.00751.x","article-title":"Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab","volume":"28","author":"Padate","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib35","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2010.01.002_bib36","first-page":"ECR49","article-title":"Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine\/cyclophosphamide and rituximab for relapsed B cell lymphoma","volume":"91","author":"Hartmann","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.20200","article-title":"Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy","volume":"77","author":"Isobe","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib38","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2141.2002.03778.x","article-title":"Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma","volume":"119","author":"Song","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","article-title":"Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation","volume":"87","author":"Lee","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib41","article-title":"Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients","author":"Levi","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLM.2005.n.053","article-title":"Fatal West Nile virus infection after rituximab\/fludarabine--induced remission for non-Hodgkin's lymphoma","volume":"6","author":"Mawhorter","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib44","first-page":"1683","article-title":"Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis","volume":"35","author":"Lutt","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib45","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib46","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib47","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib48","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib49","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib51","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428190802688509","article-title":"Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib54","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.22666","article-title":"Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials","volume":"109","author":"Rafailidis","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib55","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib56","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib57","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib59","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib60","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib61","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib62","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib63","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","article-title":"B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period","volume":"49","author":"Lim","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","article-title":"Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"77","author":"Nishio","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib67","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib68","first-page":"256","article-title":"Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy","volume":"71","author":"Sekine","year":"2000","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib69","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","article-title":"Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy","volume":"54","author":"Hui","year":"2005","journal-title":"Gut"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib70","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1042819031000151923","article-title":"Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy","volume":"45","author":"Tsutsumi","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.20540","article-title":"Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma","volume":"81","author":"Ozgonenel","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib72","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2169\/internalmedicine.45.1590","article-title":"Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab","volume":"45","author":"Sera","year":"2006","journal-title":"Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib73","doi-asserted-by":"crossref","first-page":"a423","DOI":"10.1136\/bmj.39490.680498.BE","article-title":"Fatal reactivation of hepatitis B after chemotherapy for lymphoma","volume":"337","author":"Dillon","year":"2008","journal-title":"BMJ"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib75","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00277-004-0899-y","article-title":"Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP","volume":"83","author":"Dai","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib76","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","article-title":"How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation","volume":"113","author":"Liang","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib77","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib78","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1182\/blood-2009-04-215061","article-title":"Treatment of viral hepatitis B infection in patients receiving intensive immunosuppressive therapies","volume":"113","author":"Genet","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib79","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2133.2006.07451.x","article-title":"Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma","volume":"155","author":"Perceau","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib80","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib82","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/10428190902779257","article-title":"Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating","volume":"50","author":"Carson","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib83","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab","volume":"361","author":"Wenning","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib84","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/JCM.41.10.4605-4610.2003","article-title":"Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in . 2000","volume":"41","author":"Archimbaud","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib85","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejim.2006.05.002","article-title":"Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment","volume":"17","author":"Klepfish","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib86","first-page":"1006","article-title":"Rituximab for refractory childhood autoimmune hemolytic anemia","volume":"4","author":"Motto","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ajh.21341","article-title":"Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases","volume":"84","author":"Bussone","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib88","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-006-0202-5","article-title":"Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology","volume":"86","author":"Dungarwalla","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib89","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaad.2004.06.007","article-title":"Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)","volume":"51","author":"Morrison","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib90","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/173.4.1034","article-title":"Pneumocystis carinii infection in transgenic B cell-deficient mice","volume":"173","author":"Marcotte","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib91","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4049\/jimmunol.171.3.1423","article-title":"Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody","volume":"171","author":"Lund","year":"2003","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib92","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","article-title":"B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection","volume":"176","author":"Lund","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib93","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1432-2277.2009.00903.x","article-title":"Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy","volume":"22","author":"Nishida","year":"2009","journal-title":"Transplant Int"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib96","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2008.07487.x","article-title":"Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response","volume":"144","author":"Parodi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib97","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.transproceed.2006.06.131","article-title":"Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients","volume":"38","author":"Basse","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib98","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpeds.2006.10.067","article-title":"Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases","volume":"150","author":"El-Hallak","year":"2007","journal-title":"J Pediatr"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib99","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib100","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib101","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2006.05.009","article-title":"Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris","volume":"55","author":"El Tal","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2010.01.002_bib102","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00007890-200607152-00164","article-title":"Monitoring for infectious complications of campath 1h and rituxan(r) induction therapy in crossmatch (cmx) positive kidney transplant patients receiving intravenous gammaglobulin desensitization","volume":"82","author":"Vo","year":"2006","journal-title":"Transplantation"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib103","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2004.00438.x","article-title":"Management of an ABO-incompatible lung transplant","volume":"4","author":"Banner","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-3089.2006.00279.x","article-title":"ABO-incompatible kidney transplantation of an 8-yr-old girl with donor\/recipient-constellation A1B\/B","volume":"13","author":"Ahlenstiel","year":"2006","journal-title":"Xenotransplantation"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.2008.00902.x","article-title":"Impact of rituximab therapy for treatment of acute humoral rejection","volume":"23","author":"Kaposztas","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib106","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.transproceed.2008.07.046","article-title":"Rituximab in highly sensitized kidney transplant recipients","volume":"40","author":"Munoz","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib107","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.healun.2004.09.003","article-title":"Treatment of vascular rejection with rituximab in cardiac transplantation","volume":"24","author":"Garrett","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-0012.2007.00700.x","article-title":"Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients","volume":"21","author":"Grim","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","author":"Kamar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5414\/CNP66395","article-title":"Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia","volume":"66","author":"Basse","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib111","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","article-title":"Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease","volume":"33","author":"Imashuku","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib112","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357900701809068","article-title":"Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma","volume":"26","author":"Walker","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib113","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","article-title":"Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin","volume":"146","author":"Cooper","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib114","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pbc.21965","article-title":"Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)","volume":"52","author":"Rao","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib115","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib116","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","article-title":"Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174","volume":"5","author":"Bearden","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3960\/jslrt.49.9","article-title":"Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP","volume":"49","author":"Takata","year":"2009","journal-title":"J Clin Exp Hematop"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib118","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib119","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/ard.2007.071878","article-title":"Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab","volume":"66","author":"Gelinck","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/eji.200839148","article-title":"How B cells shape the immune response against Mycobacterium tuberculosis","volume":"39","author":"Maglione","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12016-008-8074-1","article-title":"Rituximab: beyond simple B cell depletion","volume":"34","author":"Kessel","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib122","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.002_bib123","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631000003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631000003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:17Z","timestamp":1758522077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719631000003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S003719631000003X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab-Associated Infections","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}